Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for healing diabetic foot ulcers
NL-OMON61023Phase 4Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of semaglutide in diabetic foot ulcer (DFU) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Time to wound closure. Started Jul 2026; status: recruiting.
02
Drugs
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NL-OMON61023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61023.